Our Story Cellectis has 21 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). TALEN® is a registered trademark owned by Cellectis. Editing Life Here are some of our milestones 1999 2005 2007 2008 2010 2011 2014 2015 2016 2018 2019 2020 1999: Cellectis is founded In 2000, Institut Pasteur grants exclusive rights on 9 patent families, including several based on André Choulika’s research, genesis of the gene editing field. PREVIOUS NEXT Partners Our partners share the same objective to develop allogeneic cancer therapies that will benefit patients with unmet medical needs around the world. LEARN MORE LEGAL NOTICEGLOSSARYMEDIA LIBRARYCONTACTCOMMUNITY GUIDELINES Subsidiary: Calyxt Inc.

Products Product candidates Cellectis is pioneering robust first-in-class allogeneic CAR T-cell programs that address multiple unmet cancer needs. These programs were designed with simplicity, availability and cost-effectiveness for patients. READ MORE UCARTs UCARTs are “off-the-shelf” allogeneic product candidates, whose production can be industrialized and thereby standardized with consistent pharmaceutical release criteria, over time and from batch to batch. READ MORE Therapeutic indications Our product candidates, based on gene-edited allogeneic T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancer cells. READ MORE Manufacturing Our comprehensive, scalable, efficient and cost-effective manufacturing process generates highly potent CAR T therapies. READ MORE LEGAL NOTICEGLOSSARYMEDIA LIBRARYCONTACTCOMMUNITY GUIDELINES Subsidiary: Calyxt Inc.